Download PDF
Drug Res (Stuttg)
DOI: 10.1055/a-2769-1965
Short Communication

Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles

Authors

  • Pranay Renukuntla 

    1   Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad, India
    2   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India

  • Sai Charitha Mullaguri

    1   Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad, India

  • Divya Presingu

    1   Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad, India
    2   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India

  • Rama Krishna Kancha

    1   Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad, India

  • Jagadeshwar Reddy Thota 

    1   Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad, India
    2   Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
Further Information
Also available at
   Permissions and Reprints

Abstract

ABL kinase inhibitors have transformed the clinical management of chronic myelogenous leukemia; yet, the metabolic consequences of their use remain largely unexplored. In the current study, using K562 cell lines, the metabolic impact of five ABL kinase inhibitors, such as imatinib, dasatinib, nilotinib, ponatinib, and axitinib, was studied. Comparative metabolic profiling revealed both common and inhibitor-specific metabolic alterations. Pathway enrichment analysis identified significant downregulation in starch and sucrose metabolism, nucleotide sugar metabolism and sphingolipid metabolism. These results offered insights to guide the development of treatment strategies for overcoming the drug resistance in chronic myelogenous leukemia as well as managing the associated toxicities.

Keywords

Anticancer drugs - cancer - drug research

Supplementary Material



Publication History

Received: 29 July 2025

Accepted after revision: 09 December 2025

Article published online:
22 January 2026

© 2026. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany